Bioxytran (BIXT) Q2 2026 earnings summary

Executive summary

• Remains a clinical-stage pharmaceutical company focused on developing therapeutics for stroke and viral diseases, with no revenue generated to date and operations funded by equity and debt offerings.

• Completed patient recruitment for a Phase 1b/2a COVID-19 trial in India; results expected within 90 days, with a Phase 3 trial planned pending positive outcomes.

• U.S. FDA-approved IND for a COVID-19 trial, with initiation expected in Q3 2026.

• Significant progress in animal studies for its acellular oxygen carrier (BXT-25), with further preclinical studies planned.

Financial highlights

• Net loss for Q2 2026 was $619,929, compared to net income of $35,439 in Q2 2025; net loss for the six months ended June 30, 2026, was $2,688,918, up from $1,318,196 in the prior year period.

• Operating expenses for the six months ended June 30, 2026, totaled $2,587,653, up from $739,219 year-over-year, driven by a one-time CEO performance grant of $1,278,600.

• Cash at June 30, 2026, was $177,384, down from $509,914 at December 31, 2025.

• Accumulated deficit reached $23,733,164 as of June 30, 2026.

• Net cash used in operating activities was $588,383 for the six months ended June 30, 2026.

Outlook and guidance

• Management estimates a need to raise at least $3.7 million to fund operations for the next 15 months; current cash is insufficient to fund operations beyond September 2026.

• Plans to seek additional capital through private placements and public offerings; failure to secure funding may require scaling back operations.

• Anticipates publication of clinical trial results and initiation of new trials in the coming quarters, contingent on funding.